openPR Logo
Press release

Colon Cancer - Pipeline Review, H1 2017

07-17-2017 02:59 PM CET | Health & Medicine

Press release from: Report Hive

Report Hive Market Research Released a New Research Report of 745 pages on Title " Colon Cancer - Pipeline Review, H1 2017 "with detailed Analysis, Forecast and Strategies.

Colon Cancer - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer - Pipeline Review, H1 2017, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Request Free Research Sample: https://www.reporthive.com/request-sample.php?id=931465

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 12, 35, 4, 168 and 21 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 44 and 16 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction 7
Colon Cancer - Overview 8
Colon Cancer - Therapeutics Development 9
Colon Cancer - Therapeutics Assessment 42
Colon Cancer - Companies Involved in Therapeutics Development 64
Colon Cancer - Drug Profiles 136
Colon Cancer - Dormant Projects 692
Colon Cancer - Discontinued Products 703
Colon Cancer - Product Development Milestones 704
Appendix 714

Browse Full Report: https://www.reporthive.com/details/colon-cancer-pipeline-review-h1-2017

Key questions answered in the report

· What will the market size and the growth rate be in 2021?
· What are the key factors driving the Colon Cancer Market?
· What are the key market trends impacting the growth of the Colon Cancer Market?
· What are the challenges to market growth?
· Who are the key vendors in this market space?
· What are the market opportunities and threats faced by the vendors in the Colon Cancer Market?
· Trending factors influencing the market shares of the Americas, APAC, and EMEA?
· What are the key outcomes of the five forces analysis of the Colon Cancer Market?

We are a leading repository of market research reports and solutions catering to industries like Comm & Technology, Energy & Power, Food And Beverages, Automotive & Transportation, Healthcare & Life Science etc. This large collection of reports assists organizations in decision-making on aspects such as market entry strategies, market sizing, market share analysis, competitive analysis, product portfolio analysis and opportunity analysis among others. We also assist in determining the best suited and targeted report from our large repository of global reports, company-specific reports and country-level reports.

Mike Ross
Marketing Manager
mike.ross@reporthive.com
http://www.reporthive.com
Phone: +1 312-604-7084
Sainath Nagar, Vadgaon Sheri,
Pune, Maharashtra 411014

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Colon Cancer - Pipeline Review, H1 2017 here

News-ID: 627434 • Views: 111

More Releases from Report Hive

Corporate Performance Management (CPM) Software Market 2019: By Adaptive Insight …
According to this study, over the next five years the Corporate Performance Management (CPM) Software market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2023, from US$ xx million in 2017. In particular, this report presents the global revenue market share of key companies in Corporate Performance Management (CPM) Software business, shared in Chapter 3. This report presents a comprehensive
Investment Management Solutions Market 2019: Misys, SS&C Tech, SimCorp, Eze Soft …
According to this study, over the next five years the Investment Management Solutions market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2023, from US$ xx million in 2017. In particular, this report presents the global revenue market share of key companies in Investment Management Solutions business, shared in Chapter 3. This report presents a comprehensive overview, market shares and
Social Customer Service Software Market 2019: Zendesk, Salesforce, Freshworks, S …
According to this study, over the next five years the Social Customer Service Software market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2017. In particular, this report presents the global revenue market share of key companies in Social Customer Service Software business, shared in Chapter 3. This report presents a comprehensive overview, market
Auto Loan Origination Software Market 2019: DH Corp, Lending QB, Black Knight, I …
According to this study, over the next five years the Auto Loan Origination Software market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2023, from US$ xx million in 2017. In particular, this report presents the global revenue market share of key companies in Auto Loan Origination Software business, shared in Chapter 3. This report presents a comprehensive overview, market

All 5 Releases


More Releases for Colon

Colon Cleansing Supplements Market by Key Players - Vita Balance, PRIVATELABELSU …
Global Colon Cleansing Supplements Market: Snapshot Colon cleansing is essential if one needs to lose a few pounds of weight, solve acne problems, or improve their digestive system. There are several supplements are now available that adequately match the requirements and according to the findings of this study, the demand for them would be expanding profitably over the course of 2017 to 2027, gaining traction from increased awareness levels among the
Colon Cancer Market Prevalent Opportunities upto 2021
Colon cancer is the cancer of large intestine which form the lower part of the digestive system. The disease usually begins with a small, benign clusters of cells known as adenomatous polyps. If left untreated, these polyps may result into colon cancer. Therefore, regular screening for polyps through colonoscopy in order to prevent it transforming to colon cancer is recommended. Change in bowel habits or blood in stool are the
Global Therapeutic Landscape Of Colon Cancer Industry Pipeline Review, 2017
Overview Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools
Colon Cancer Market Perceive Robust Expansion by 2021
Colon cancer is the cancer of large intestine which form the lower part of the digestive system. The disease usually begins with a small, benign clusters of cells known as adenomatous polyps. If left untreated, these polyps may result into colon cancer. Therefore, regular screening for polyps through colonoscopy in order to prevent it transforming to colon cancer is recommended. Change in bowel habits or blood in stool are the
Colon Cancer Therapeutic Pipeline Market Review, H2 2017
Summary Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools
Colon Cancer Pipeline Therapeutics Review H1 2017
Colon Cancer Pipeline Drugs Review H1 2017 provides an overview of the Colon Cancer therapeutics (Oncology) pipeline landscape. Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. For More on Colon Cancer Pipeline Review H1 2017 Report Inquire @ https://tinyurl.com/Colon-Cancer-Therapeutic . Report Description: Pharmaceutical guide Colon Cancer - Pipeline